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Abstract
Background: Circulating micro-RNAs have been proposed as a novel class of cardiovascular (CV) biomarkers, but whether
they meet analytical requirements and provide additional information to establish risk indices have not been established.
miR-210 levels are increased in subjects with low VO2 max, which is a recognized risk factor in patients with aortic stenosis
(AS), and we hypothesized that circulating miR-210 levels may be increased in patients with AS and associated with a poor
prognosis.
Methods: We measured circulating miR-210 levels by real-time PCR in 57 patients with moderate to severe AS and in 10
age- and gender-matched healthy controls. The merit of miR-210 as a biomarker was assessed according to established
criteria, including by comparing miR-210 levels with NT-proBNP and miR-22 levels, which is another miRNA biomarker
candidate.
Results: All patients and control subjects had miR-210 levels within the range of detection (Cq,35) and the analytical
variability was low. Circulating miR-210 levels were 2.060.2 [mean6SEM] fold increased in AS patients compared to controls
(p = 0.002), whereas miR-22 levels were not differently expressed in the AS patients (0.1260.06 fold increase, p = 0.45). The
increase in miR-210 levels in AS patients was comparable to the increment in NT-proBNP levels: [AUC] 0.82 (95% CI 0.70–
0.90) vs. 0.85 (0.75–0.93), respectively, p = 0.71. During a median follow-up of 1287 days, 15 patients (26%) died. There was a
significant association between higher circulating levels of miR-210 and increased mortality during follow-up: hazard ratio
[supra- vs. inframedian levels] 3.3 (95% CI 1.1–10.5), p = 0.039. Adjusting for other risk indices in multivariate analysis did not
attenuate the prognostic merit of circulating miR-210 levels.
Conclusion: Circulating miR-210 levels are increased in patients with AS and provide independent prognostic information
to established risk indices. Analytical characteristics were also excellent supporting the potential of micro-RNAs as novel CV
biomarkers.
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Introduction
Current risk stratification in patients with aortic stenosis (AS) is
based on symptoms (dyspnea, syncope, chest pain) and the
identification of aortic valve orifice narrowing by echocardiogra-
phy [1]. However, as the majority of patients with AS are elderly,
a large proportion of the patients have a sedentary life style,
causing a delay in the recognition of symptoms [1]. Hence,
irreversible myocardial damage may occur before the patients
experience symptoms, and additional means to identify high-risk
patients are needed [2].
MicroRNAs (miRNAs) are short (,22) nucleotide non-coding
RNAs that influence cell function by regulating messenger-RNA
stability and function [3]. miRNAs have the ability to regulate
multiple downstream protein targets, and individual miRNAs have
been found to be of crucial importance for myocardial function
[3]. Moreover, the release of miRNAs to the circulation and the
transport of miRNAs throughout the body bound to proteins [4],
lipids [5], or as part of microvesicles [4] suggest that miRNAs may
represent a new class of cardiovascular (CV) biomarkers [6]. With
individual miRNAs regulating multiple downstream protein
pathways, it has been postulated that individual miRNAs may
provide integrated information on several pathophysiological axes
[3]. However, although miRNAs seem to have potential as CV
biomarkers, it is important that all biomarker candidates are
examined according to established criteria [7]. These criteria
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include analytical characteristics (accuracy and reproducibility)
and that the biomarker provides incremental information to the
information that can be obtained from established risk indices.
Currently, few studies have assessed miRNA biomarkers according
to these criteria. miRNAs also cluster in networks based on
common physiological properties and most previous miRNA
biomarker studies have explored several miRNAs in combination
[8,9]. From a statistical point of view, the multimarker approach
carries the risk of false positive results due to the testing of several
biomarkers in the same cohort. Moreover, a multimarker
approach is less user-friendly as several biomarkers need to be
assayed and considered together. Hence, we believe that for
biomarker research the exploration of individual miRNAs is
important. An interesting miRNA biomarker candidate is miR-
210 as miR-210 production is closely linked to cellular hypoxia
[10]. We recently also found circulating miR-210 levels to be the
most strongly increased miRNA in subjects with low VO2 max of
the 720 miRNAs that were tested [11]. The close association
between circulating miR-210 levels and aerobic fitness suggest that
miR-210 may have merit as a prognostic biomarker in patients
with cardiovascular disease (CVD) and especially in patients with
aortic stenosis (AS) as aerobic capacity is an important risk factor
and used for selection to surgery in AS [12]. Accordingly, in this
study we wanted to assess whether circulating miR-210 levels fulfill
the proposed criteria for novel biomarkers in a cohort of patients
with moderate to severe AS.
Results
Clinical and Echocardiographical Data of AS Patients and
Control Subjects
The patients and control subjects were evenly matched on age,
gender, and body mass index (BMI) (Table 1). Only a minority of
the AS patients were considered to be in New York Heart
Association (NYHA) functional class III/IV, but N-terminal pro-
B-type natriuretic peptide (NT-proBNP) levels were significantly
increased in AS patients compared to control subjects. The
proportion of comorbidity was high in the AS patients, and this
was also reflected in medication use among the AS patients.
Compared to the control subjects, patients with AS had reduced
aortic valve orifice area and increased velocity and pressure
gradient over the valve, evidence of left ventricular (LV)
hypertrophy, and impaired LV relaxation as assessed by E/e’
(Table 2).
miR-210 Levels in Patients with AS
All patients and control subjects had miR-210 levels within the
range of detection (Cq,35; range Cq 29–32). The coefficient of
variation for the samples run in triplet was 0.6% for both AS
patients and the control subjects. Coefficient of variations for the
spike-in control synthetic C. elegans miR-39 (cel-miR-39) was
2.4% for AS patients (n = 57) and 2.2% for the control subjects
(n = 10) and the raw Cq values are presented in Figure 1.
miR-210 levels were higher in AS patients compared to the
control subjects: 3.060.2 vs. 1.060.5, p = 0.002 (Fig. 2). In
contrast, miR-22 levels (Cq 27–30), which is another miRNA
biomarker candidate, were not increased in the AS patients
(Table 1, Fig. 2). The area under the curve as assessed by receiver
operating characteristics (ROC-AUC) to separate AS patients
from the control subjects of miR-210 levels were comparable to
that of NT-proBNP levels: 0.82 (95% confidence interval [CI]
0.70–0.90) vs. 0.85 (0.75–0.93), respectively, p= 0.71. miR-210
levels were significantly correlated with miR-22 levels in the AS
patients (r = 0.46, p,0.001), but not in the control subjects
(Table 3). There was also a modest but significant inverse
correlation between miR-210 levels and LV end-diastolic dimen-
sion in patients with AS. No other significant correlations were
found between clinical and echocardiographical variables in AS
patients or control subjects. As assessed by logistic regression, there
were no significant associations between miR-210 levels over the
median and clinical variables, including presence of coronary
artery disease (CAD), nor echocardiographical variables, although
the associations with left atrial area (odds ratio [OR] 0.92 [95% CI
0.84–1.003], p= 0.06) and NT-proBNP levels (OR 1.54 [0.98–
2.41], p = 0.06) were of borderline significance. miR-210 levels in
patients with and without CAD were 3.160.4 vs. 2.860.3 (fold
change vs. control subjects), respectively, p = 0.56.
Prognostic Utility of miR-210 Levels in Patients with AS
During a median follow-up of 1287 days (quartile [Q] 1–3
1045–1400 days), 15 (26%) of the AS patients died. A miR-210
level over the median was associated with increased risk of
mortality (p = 0.029 by the log-rank test, Fig. 3). High NT-proBNP
and miR-210 levels, together with history of hypertension and
increasing eccentric LV hypertrophy based on calculation of
relative wall thickness, were associated with mortality in multi-
variate Cox proportional hazard regression analysis (Table 4). The
prognostic accuracy of miR-210 for all-cause mortality was
comparable to the accuracy of NT-proBNP levels: AUC=0.64
(95% CI 0.50–0.76) vs. AUC=0.67 (0.53–0.79), respectively,
p = 0.83.
Discussion
The principal results of this study are (1) only minor variation
for the spike-in control cel-miR-39 across different samples, (2)
circulating miR-210 levels are increased in patients with AS, and
(3) circulating miR-210 levels were associated with the risk of
mortality during follow-up, independently of established risk
indices. miRNA biomarkers thus seem to meet the requirements
for analytical accuracy and reproducibility, and our data support
circulating miR-210 as a novel CV biomarker that should be
further tested in larger patient groups.
To the best of our knowledge, our study is the first to examine
miRNA biomarkers in a stringent manner according to the criteria
proposed by Morrow and de Lemos [7]. Analytical accuracy and
reproducibility are key factors when determining whether a
biomarker may have clinical potential. We found the analytical
stability to be excellent when measuring cel-miR-39 levels across
different samples of AS patients and in the control subjects. The
coefficient of variations of 2.4% and 2.2%, respectively, are well
within the range that we also see for commercially available
protein assays, including previously reported coefficient of
variations for two high-sensitivity troponin assays in our laboratory
[13]. Furthermore, cDNA synthesis and quantitative real-time
PCR (RT-qPCR) analyses demonstrated minimal variability with
a mean coefficient of variation of 0.6% for the samples assayed in
triplet. Interestingly, we also found cel-miR-39 expression to be in
the same range as previous reported for Taqman-based analyses
[14]. Pertinent to this, although miRNA raw Cq levels are known
to be highly variable according to RNA extraction and miRNA
detection techniques, miR-210 and miR-22 levels in our study
were well within the range of detection with Cqs of 29–32 and 27–
30, respectively. We used relative quantification, and miR-210
levels are presented as fold change to the levels in the control
subjects, which is the strategy also employed by other groups [8].
We found circulating miR-22 levels to be unaltered in patients
with AS compared to the control subjects, which makes it unlikely
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Table 1. Baseline characteristics of the patients with aortic stenosis and the control subjects.
AS (n=57) Ctr (n =10) p
Age (y) 7561 7461 0.72
Women 31 (54%) 3 (30%) 0.19
BMI 2661 2561 0.47
NYHA functional class III/IV 19 (33%)
Creatinine clearance (mL/min) 70 (52–86)
Coronary artery disease 38 (67%)
Hypertension 29 (51%)
Diabetes mellitus 8 (14%)
Atrial fibrillation 12 (21%)
COPD 5 (9%)
Medication
b-blocker 27 (47%)
Ca2+ channel blocker 9 (16%)
ACEI 10 (18%)
AII-blocker 11 (19%)
Aspirin 32 (56%)
Warfarin 11 (19%)
Diuretics 25 (44%)
Statin 34 (60%)
Aldosterone antagonist 6 (11%)
NT-proBNP (pg/mL) 785 (334–2395) 156 (56–342) ,0.001
miR-210 levels (fold change vs. ctr) 3.060.2 1.060.5 0.002
miR-22 levels
(fold change vs. ctr)
1.1260.06 1.0060.18 0.45
BMI, body mass index; NYHA class, New York Heart Association functional class; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme
inhibitor; AII-blocker, angiotensin II blocker; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and miR, micro-RNA.
doi:10.1371/journal.pone.0091812.t001
Table 2. Echocardiographical data in the patients with aortic stenosis and control subjects.
AS (n=57)* Ctr (n=10) p
Left atrial area (cm2) 22.460.9 18.461.6 0.07
LV end-diastolic dimension (cm) 5.260.09 5.260.3 0.89
LVEF (%) 5761 6061 0.45
Fractional shortening (%) 37.761.4 37.361.5 0.92
LV cardiac index (L/minm2) 2.760.07 2.760.2 0.79
Aortic valve area (cm2) 0.760.03 3.260.2 ,0.001
Aortic valve velocitymax (m/s) 4.560.2 1.360.07 ,0.001
Aortic valve mean pressure gradient (mmHg) 5664 460.4 ,0.001
Interventricular septal end-diastolic dimension (cm) 1.260.03 0.960.06 ,0.001
LV end-diastolic posterior wall dimension (cm) 1.060.02 0.860.04 0.002
E/e’ 19.161.7 8.060.8 0.009
E/A ratio 1.060.1 0.860.06 0.32
Mitral valve deceleration time (ms) 236610 239619 0.90
Relative wall thickness 0.4360.01 0.3360.01 ,0.001
LV mass (g) 232610 169621 0.012
LV, left ventricular; and LVEF, left ventricular ejection fraction.
*n = 53 for E/e’ and n = 52 for E/A ratio.
doi:10.1371/journal.pone.0091812.t002
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that the increment in miR-210 levels is a result of a general
upregulation of all circulating miRNAs in AS. Analogous to our
previous publication on circulating miRNAs and physical capacity
[11], we normalized miR-210 levels against miR-425 levels. We
chose miR-425 levels as the normalization strategy as we
previously have found miR-425 to be expressed closest to the
mean Cq of all miRNAs (geomean) in two screening studies
exploring 720 miRNAs (34 subjects in total) with correlation
coefficients of r = 0.93 (n= 24) and r = 0.94 (n= 10) between
geomean and miR-425 Cq values, respectively (Figure S1). Hence,
in our experience miR-425 is the miRNA that best reflects the
total miRNA expression in an individual. Leading researchers in
the field also advocate a combination of a spike-in control to assess
extraction quality and the use of a stable miRNA for normaliza-
tion [15,16]. Furthermore, no study has yet reported circulating
miR-425 levels to be specifically influenced by CVD, and other
Figure 1. Extraction from serum and RT-qPCR of the spike-in control cel-miR-39 were performed with minimal variation between
samples (CV 2.4% for AS patients [#1–36 and #38–58] and 2.2% for the control subjects [#59–74]), which indicates that miRNAs
seem to meet the analytical requirements proposed for novel biomarkers. Data are presented as the absolute Cq values.
doi:10.1371/journal.pone.0091812.g001
Figure 2. miR-210 levels were significantly increased in patients with AS compared to age- and gender-matched control subjects,
whereas miR-22 levels were not altered. The horizontal line within the box represents the median level, the boundaries of the box quartiles 1–3,
and the whiskers range (maximum value restricted to 1.56interquartile range from the median). *p,0.01.
doi:10.1371/journal.pone.0091812.g002
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Table 3. Correlations in AS patients and control subjects (Ctr) between miR-210 levels and clinical and echocardiographical
parameters of myocardial structure and function.
Variable AS patients (n=57)* Ctr (n=10)
r p r p
Age 0.22 0.10 0.18 0.62
Gender 20.06 0.64 20.42 0.23
BMI 20.13 0.33 20.05 0.89
Creatinine Clearance 20.15 0.26 – –
NT-proBNP levels 0.18 0.18 20.34 0.33
miR-22 levels 0.46 ,0.001 20.14 0.72
Left atrial area (cm2) 20.23 0.08 20.55 0.10
LV end-diastolic dimension (cm) 20.26 0.049 20.45 0.20
LVEF (%) 0.009 0.95 20.21 0.57
Fractional shortening (%) 20.08 0.55 0.36 0.31
LV cardiac index (L/minm2) 20.11 0.41 20.54 0.31
Aortic valve area (cm2) 20.09 0.49 20.20 0.58
Aortic valve velocitymax (m/s) 20.05 0.74 20.44 0.20
Aortic valve mean pressure gradient (mmHg) 20.008 0.95 20.05 0.89
Interventricular septal end-diastolic dimension (cm) 0.006 0.97 20.04 0.92
LV end-diastolic posterior wall dimension (cm) 20.03 0.85 20.23 0.52
E/e’ 0.02 0.86 0.14 0.71
E/A ratio 0.16 0.27 0.04 0.91
Mitral valve deceleration time (ms) 20.19 0.16 0.30 0.39
Relative wall thickness 0.16 0.25 0.40 0.25
LV mass (g) 20.14 0.29 20.33 0.35
BMI, body mass index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and miR, micro-RNA; LV, left ventricular; and LVEF, left ventricular ejection fraction.
*n = 53 for E/e’ and n = 52 for E/A ratio.
doi:10.1371/journal.pone.0091812.t003
Figure 3. Assosciation between miR-210 levels and mortality during follow-up with miR-210 levels divided by the median (p=0.029
by the log-rank test).
doi:10.1371/journal.pone.0091812.g003
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Table 4. Predictors for mortality during follow-up by univariate and multivariate Cox proportional hazard regression analysis.
Univariate analysis
Hazard ratio 95% CI p
Age, per 1 y increase 1.06 0.99–1.14 0.09
Male gender 2.60 0.89–7.63 0.08
BMI, per 1 unit increase 0.91 0.80–1.04 0.16
NYHA functional class III/IV 1.13 0.39–3.32 0.82
Creatinine clereance, mL/min 0.98 0.96–1.003 0.08
Coronary artery disease 1.52 0.49–4.79 0.47
Hypertension 0.29 0.09–0.90 0.032
Diabetes mellitus 0.93 0.21–4.11 0.92
Atrial fibrilliation 0.22 0.03–1.70 0.15
COPD 3.91 1.09–14.1 0.037
Medication
b–blocker 0.95 0.34–2.62 0.92
Ca2+ channel blocker 0.32 0.04–2.45 0.27
ACEI 1.86 0.59–5.85 0.29
AII–blocker 0.034 0.001–6.20 0.20
Aspirin 1.65 0.56–4.83 0.36
Warfarin 0.25 0.03–1.91 0.18
Diuretics 1.12 0.41–3.19 0.83
Statin 0.96 0.34–2.69 0.94
Aldosterone antagonist 2.57 0.72–9.16 0.15
Left atrial area (cm2) 0.98 0.91–1.07 0.09
LV end–diastolic dimension (cm) 1.85 0.87–3.93 0.11
LVEF (%) 0.96 0.92–1.009 0.11
Fractional shortening (%) 0.96 0.92–1.008 0.10
LV cardiac index (L/minm2) 0.88 0.32–2.48 0.81
Aortic valve area (cm2) 6.77 0.81–56.78 0.08
Aortic valve velocitymax (m/s) 0.74 0.47–1.17 0.20
Aortic valve mean pressure gradient (mmHg) 0.99 0.97–1.009 0.26
Interventricular septal end-diastolic dimension (cm) 0.37 0.02–5.69 0.47
LV end-diastolic posterior wall dimension (cm) 0.037 0.002–0.88 0.041
E/e’ 1.03 1.00–1.07 0.08
E/A ratio 0.55 0.16–1.91 0.35
Mitral valve deceleration time (ms) 1.00 0.99–1.007 0.93
Relative wall thickness (per 0.1 increase) 0.44 0.21–0.92 0.028
LV mass (g) 1.00 0.99–1.007 0.92
Aortic valvular surgery 0.10 0.03–0.34 ,0.001
NT-proBNP levels 1.71 1.04–2.81 0.036
miR-210 levels (supramedian) 3.34 1.06–10.49 0.039
Multivariate analysis
Hypertension 0.21 0.07–0.70 0.011
Relative wall thickness (per 0.1 increase) 0.39 0.18–0.85 0.018
NT-proBNP levels 2.20 1.17–4.14 0.014
miR-210 levels (supramedian) 4.79 1.40–16.45 0.013
BMI, body mass index; NYHA class, New York Heart Association functional class; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme
inhibitor; AII-blocker, angiotensin II blocker; LV, left ventricular; LVEF, left ventricular ejection fraction NT-proBNP, N-terminal pro-B-type natriuretic peptide; and miR,
micro-RNA.
NT-proBNP levels were transformed by the natural logarithm prior to regression analysis due to a right-skewed distribution.
doi:10.1371/journal.pone.0091812.t004
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groups have also proposed miR-425 as a normalization strategy
[17].
We found miR-210 levels to provide incremental prognostic
information to established risk indices in patients with AS, which is
a sine qua non criterion for a biomarker to have clinical potential
[7]. Thus, miR-210 levels seem to provide information on
pathophysiology not covered by the established CV risk indices.
The additional information obtained by measuring miR-210 levels
is also demonstrated by the lack of associations between miR-210
levels and clinical and echocardiographical variables and NT-
proBNP levels in linear regression analysis. Currently, no
information is available concerning the cellular source responsible
for the increased circulating miR-210 levels in AS. However, both
the endothelium and the myocardium may contribute to
circulating miR-210 levels as these tissues increase their miR-
210 production during cellular hypoxia and injury [10,18]. In
contrast, platelets do not seem to be an important contributor to
miR-210 levels [19]. Of note, miR-425 does not appear to be a
platelet-derived miRNA, which supports our use of miR-425 as a
normalization strategy for miRNA biomarkers.
Other groups have also found circulating miR-210 levels linked
to CVD as miR-210 levels are increased in proportion to the
severity of heart failure [20,21]. Circulating miR-210 levels have
also been found elevated in patients with myocardial infarction
[22] and peripheral artery disease [23], and to provide prognostic
information independently of established risk indices in patients
with acute kidney injury [24]. In heart failure, a model for
circulating miR-210 levels as reflective of the mismatch between
impaired cardiac function and the oxygen demand of peripheral
organs has been postulated [21]. Our recent report of increased
circulating miR-210 levels in subjects with low aerobic fitness lends
some support to the model of hypoxia-mediated miR-210
increment. Hence, local supply-demand imbalance in the myo-
cardium due to LV hypertrophy could be a factor leading to
higher miR-210 levels in patients with AS [25]. This model needs
to be further explored in additional clinical and experimental
studies, but is supported by previous experimental investigations
demonstrating hypoxia inducible factor-1a regulated miR-210
expression during cellular hypoxia [26]. Accordingly, miR-210 is
most likely not a specific biomarker for AS, but rather a CV risk
marker upregulated by and associated with prognosis in patients
with AS. Additional studies are needed to confirm this model for
miR-210, but this would be analogous to most other CV
biomarkers, including NT-proBNP that are increased by several
CV etiologies and provide prognostic information across the
spectrum of CVD [27]. Whether miR-210 levels may improve
patient management, which is the final criteria for novel
biomarkers [7], cannot be assessed based on the available data
in the literature or this study. miRNA biomarkers are still in the
early stage of testing and additional and larger studies are clearly
needed to address this question.
This study has both strengths and limitations. We performed
biomarker assessment according to established criteria [7]. The
low coefficient of variations of the miRNA triplet and the spike-in
cel-miR-39 control validate the small-RNA extraction protocol
employed and the robust technical work regarding RNA
extraction and real-time PCR in our study. The extensive
echocardiographical examination and the benchmarking against
NT-proBNP levels for prognostic assessment also represent
strengths of our work. In contrast, the modest number of patients
represents a limitation. However, from a statistical point of view
the substantial event rate (26% mortality) during follow-up is
considered of more importance than the absolute number of
patients included in the study [28]. Furthermore, our final
multivariate Cox regression model includes, in addition to high
miR-210 levels, established risk factors in AS such as NT-proBNP
levels and relative wall thickness, thus supporting the validity of
our work. We acknowledge that there is no generally accepted
normalization strategy for miRNA biomarker studies. A common
alternative strategy has been to normalize against the spike-in
control cel-miR-39, but we would argue against this strategy. As
demonstrated in this study, the spike-in control presents with a
very stable Cq value, whereas the geomean may differ by 2–3 Cqs
from individual to individual (Figure S1). Accordingly, when
normalizing against cel-miR-39 levels subjects with a low overall
miRNA expression (and thus a high geomean Cq value) will be
found to have low or normal levels of the specific miRNA of
interest, although in reality this specific miRNA could be increased
compared to the expression of other miRNAs of the subject. Cel-
miR-39 has also been demonstrated to differ according to
medication [14], which reduces the quality of cel-miR-39 as the
normalization strategy.
In conclusion, we report that miR-210 may have potential as a
novel CV biomarker as analytical variation for RNA extraction
and RT-qPCR analysis was low and circulating miR-210 levels
provided prognostic information independently of established risk
indices, including NT-proBNP levels. Accordingly, additional
studies of circulating miR-210 levels in larger patient cohorts are
needed to further explore miR-210 as a CV biomarker.
Methods
Patient Cohort and Control Subjects
The study was approved by the South-Eastern Norway
Regional Ethics Committee and Oslo University Hospital,
Rikshospitalet and performed according to the Declaration of
Helsinki. All patients provided written informed consent prior to
study commencement.
We recruited 57 patients with AS referred to a European
tertiary cardiothoracic surgery centre for evaluation. The patient
recruitment was finalized in 2009 prior to the start of transcatheter
aortic valve implantation therapy, thus only open heart surgery
was available as a therapeutic option in our patients. We recruited
the patients during pre-operative assessment and thus prior to the
final decision concerning surgery. Patients with acute coronary
syndromes or primarily aortic regurgitation or right-sided valvular
heart disease were not included. Information regarding medical
history, current symptoms, medication, and functional class was
obtained from the medical records, as previously reported [29].
CAD was defined as either previous acute myocardial infarction,
previous percutaneous coronary intervention, previous coronary
artery bypass grafting, or a stenosis $50% of an epicardial artery
on angiography. Data regarding mortality until August 1, 2012
were obtained from electronic hospital records, which are
synchronized with Statistics Norway on a monthly basis.
We also recruited 13 age- and gender-matched control subjects
for this study. The control subjects were recruited outside of the
hospital, had no previous history of CVD or diabetes mellitus, and
no current symptoms of CVD, as evaluated by one researcher
(HR). Material for RNA extraction was available from 10 of the
control subjects.
Echocardiographical Examination
The patients were examined by a standard protocol for
transthoracic echocardiography using a Vivid 7 (GE Healthcare,
Horten, Norway). All images were digitally stored for later offline
analysis (Echopac, GE Vingmed). We obtained standard para-
sternal long axis and three apical views recordings in the end-
miR-210 in Aortic Stenosis
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expiratory phase with the subjects in supine left lateral position.
LV dimension, septal and posterior wall thickness, and mass were
measured as recommended [30]. We assessed LV systolic function
by calculating the ejection fraction (LVEF) according to the
modified Simpson’s rule from biplane 4-chamber and long-axis
view and by determining fractional shortening. The severity of
aortic valvular orifice narrowing was assessed by measuring aortic
valve velocity and calculating the mean pressure gradient and
aortic valve area. LV diastolic function was assessed by pulsed
Doppler transmitral peak early (E), peak late (A) and E
deceleration time. We recorded early diastolic velocity (e’) at the
base of the septal and lateral mitral annulus. All the recordings
were reviewed by one researcher (TE) with no knowledge of
circulating biomarker levels.
Blood Sampling and Protein Biochemical Analyses
Blood sampling in serum and EDTA tubes was performed by
standard venepuncture at the time of echocardiography for the
patients and control subjects. Blood samples were immediately put
on ice, processed ,30 min, and stored at 280uC prior to
transport to Akershus University Hospital for further analyses. We
measured NT-proBNP by the proBNP II assay (Roche Diagnos-
tics, Penzberg, Germany) in EDTA samples and we calculated
creatinine clearance by the Cockcroft-Gault formula.
miR Isolation
RNA was extracted from serum according to the protocol
recommended by Exiqon (Vedbæk, Denmark). In brief, we first
made QIAzol Master Mix by adding 1.25 mL 0.8 mg/mL MS2
bacterophage RNA to 800 mL QIAzol (QIAGEN Sciences,
Germantown, MN). We then added 750 mL QIAzol Master Mix
to 200 mL serum and extracted miRs by the use of chloroform,
ethanol, spin columns, and RNase free water. Cel-miR-39 was
included as a spike-in control to assess the efficiency of RNA
extraction.
Real-time PCR Analysis
We synthesized complementary DNA (cDNA) from 4 mL RNA
in a total reaction volume of 20 mL using the miRCURY LNATM
Universal RT microRNA PCR, Polyadenylation and cDNA
synthesis kit (Exiqon). miR-210, -22, -425, and cel-miR-39 levels
were measured by RT-qPCR employing pre-made (cat#204333,
cat#204606, and cat#204337) and custom-made primer assays
from Exiqon and using the HT 7900 Real-Time PCR System
(Applied Biosystems, Foster City, CA). We normalized miR-210
levels to miR-425 levels as miR-425 recently was reported as a
circulating miRNA for normalization [17] and we have found
miR-425 to be expressed closest to the geomean in two screening
studies exploring 720 miRNAs in total (n = 34) (Figure S1
demonstrating r = 0.93 and r = 0.94 for correlations between
miR-425 and geomean levels in the two screening cohorts). miR-
425 was also our normalization strategy in a previous miRNA
biomarker study [11]. For each serum sample, three cDNA
synthesis reactions were performed, and all cDNA samples were
included for RT-qPCR analysis. Samples were run on 96 well
plates and inter-plate calibration for the assays were based upon
the use of two individuals included in all plates. Relative
quantification calculations were performed according to the 2–
[delta][delta]Ct method [31] by the use of SDS 2.4 software
(Applied Biosystems). The relative microRNA expression is shown
as fold change values (log2 of RQ values), which is the strategy to
report miRNA levels also used by other groups [8].
Statistical Analysis
Continuous data are presented as mean (6 SEM) except for
NT-proBNP levels that are presented as median (Q 1–3) due to a
right-skewed distribution (assessed by the Kolmogorov-Smirnov
one sample test). We examined between group differences by the
Student’s t test or the Mann-Whitney U test as appropriate.
Categorical data are presented as absolute numbers and percent-
ages, and were compared by the Chi-square or the Fisher Exact
test. Correlations were assessed by the Pearson method. Variables
associated with a high miR-210 levels were examined by logistic
regression analysis with age, gender, BMI, NYHA functional class
(I/II vs. III/IV), comorbidities, echocardiographical variables,
estimated creatinine clearance, and NT-proBNP levels (logarith-
mical transformed) included in the model. Kaplan-Meier plots
with patients subdivided according to median miR-210 levels were
generated and crude risk compared by the log-rank test. Adjusted
risk estimates of miR-210 levels above the median and established
clinical and echocardiographical risk factors were assessed by Cox
proportional hazard regression analysis. Diagnostic and prognostic
accuracy were assessed by receiver operating characteristics
(ROC) curve analysis [32] with area under the curve (AUC)
presented with 95% CI. P-values ,0.05 were considered
significant for all analyses. Statistical analyses were performed
with SPSS for Windows version 19.0 (SPSS, Chicago, IL).
Supporting Information
Figure S1 We normalized against miR-425 levels as we
previously have found this endogenous miRNA ex-
pressed closest to the mean of all circulating miRNAs
(geomean) in two different screening cohorts with
720 miRs measured in total (r = 0.93 for n=24 and
r=0.94 for n=10, p,0.001 in both). Accordingly, our data
support miR-425 levels as a surrogate marker of the geomean and
therefore miR-425 should be appropriate for normalization.
(PDF)
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